Buenavista Equity Partners, a Spanish private equity firm specialising in the lower and mid-market segments, has announced the launch of its new healthcare fund, BV Healthcare Growth Innvierte I.
The fund has reached its target size with an initial closing of €100 million and plans to continue raising commitments to a hard cap of €150 million. This initiative represents a joint venture between Buenavista and Columbus Venture Partners, a specialist in biotech venture operations. Both companies combined sum up a total of 45 investments in the sector.
This fund is backed by Spain’s Centre for Technological Development and Innovation (CDTI), which has committed up to €58 million through its Innvierte Programme, a co-investment instrument aimed at advancing innovative therapies and drug development.
Nuria Osés, partner and head of the Healthcare strategy at Buenavista, expressed the fund’s vision: “We are very excited to announce the launch of this new fund dedicated exclusively to the healthcare sector. Buenavista is entering a new phase of growth, with a strong commitment to a sector where we are already present, and which displays great opportunities. This is not just because of its capacity for expansion, but also due to the growing demand for innovative solutions that require a higher level of investment. We aim to support companies that are addressing some of the main trends in today’s society, such as precision and personalised medicine, advanced therapies, the challenges from increased longevity and the presence of chronic diseases. In addition to generating economic value, these companies are committed to having a positive impact on society, offering solutions that improve people’s quality of life and well-being.”
Buenavista Equity Partners, established in 1996, manages over €1 billion across Private Equity, Infrastructure, and Venture Capital vehicles. Columbus Venture Partners complements this with over €400 million managed across four funds, with a proven track record in biopharmaceutical investments.
The fund will focus on innovative healthcare startups with low scientific/technological risk or very close to commercialisation to support their growth and scalability. Buenavista and Columbus will provide the capital, expertise and global reach necessary to maximise the company’s potential in the next stages of their development.
Areas of interest include pharmaceuticals, biotech products, precision medicine, diagnostic solutions, AI and big data in healthcare, digital therapies, industrial production scaling, scientific services such as CROs and CDMOs, and healthcare services. The fund plans to invest in 10-12 companies, predominantly in Spain, with individual investments of up to €15 million.
The fund’s first investment has been made in Syngoi, a Contract Development and Manufacturing Organisation (CDMO) specialising in synthetic DNA for advanced therapies, including mRNA vaccines and gene therapies. Located in Zamudio, Bizkaia, Syngoi utilises advanced facilities to streamline DNA production, reducing turnaround times and enhancing DNA purity. This investment, which also includes contributions from Columbus and Asahi Kasei Medical, will enable Syngoi to expand its production capacity to support over 25 concurrent customer projects.
Damià Tormo, Managing Partner and co-founder of Columbus Venture Partners, added: “The fund’s strategy responds to a profile of healthcare and biotechnology companies that are at a crucial stage of their development, seeking capital to expand their operations and that have scientifically proven and risk-free products. Given the lack of financing by specialised investors for this type of high-growth medical companies in Spain and in the European market, we believe that this fund fills a great gap in an area of great economic and social relevance.”
Read the orginal article: https://www.eu-startups.com/2024/12/e100-million-healthcare-fund-launched-by-private-equity-firm-buenavista-equity-partners/
